Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Weight Loss After Bariatric Surgery

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

How Does Semaglutide Work to Lose Weight?

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Unexplained Weight Loss: When It Might Signal a Health Problem

Mental Health Disorders, Weight Gain, and Exercise

Vegetarian Diets for Weight Loss

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Semaglutide and Weight Loss in Menopause

See more featured articles »

Cachexia / Wasting Syndrome

Circadian Rhythm and Weight Loss

How Oral GLP-1 Drugs Work For Weight Loss

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Does Cinnamon Help with Weight Loss?

Cachexia and Cancer

Wegovy: A Breakthrough in Weight Loss?

The Natural Molecule That Could Rival Ozempic

Military Diet: Health Risks

Latest Weight Loss News and Research

‘How low can you go?’ The shifting guidelines for blood pressure control

The patient initially came to see Mark Supiano in 2017 because her family was concerned about her short-term memory loss.

20 Mar 2026

Do artificial sweeteners increase appetite or food intake?

The study evaluates artificial sweeteners' role in appetite regulation, showing no significant effects on hunger or energy intake during weight management.

20 Mar 2026

How long should you take GLP-1 drugs? Study links longer use to lower heart risk

Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major cardiovascular events compared with sulfonylureas, with benefits increasing over time. Discontinuation or interruption was associated with a progressive loss of this protective effect, with risks approaching those of comparator therapy.

19 Mar 2026

Python blood compound could lead to new weight loss therapies

University of Colorado Boulder researchers have discovered an appetite-suppressing compound in python blood that helps the snakes consume enormous meals and go months without eating yet remain metabolically healthy.

19 Mar 2026

GLP-1 medications linked to reduced psychiatric hospital visits

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows.

18 Mar 2026

Stopping GLP-1 treatment linked to increase in risk of major cardiovascular events

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits.

18 Mar 2026

Study finds GLP-1 medicines cut fat while preserving muscle function

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in absolute muscle mass and no disproportionate loss of muscle function. In mice, physical performance improved, while in a small 12-week human pilot trial, strength was preserved despite reduced thigh muscle size.

18 Mar 2026

More US adolescents are obese but fewer are trying to lose weight

The rising obesity rates in American adolescents, coupled with declining weight-loss efforts, signal urgent needs for targeted public health interventions.

18 Mar 2026

Weight-loss drugs linked to preterm birth risk in women with pre-existing diabetes

Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes.

17 Mar 2026

Tailored prediabetes treatment may better prevent Type 2 diabetes

A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, tailored prevention approach for those with the highest risk of developing Type 2 diabetes, according to preliminary research presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026.

17 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

Biodegradable sanitary pads made from water hyacinth pass safety and absorbency tests in new study

Researchers developed a biodegradable sanitary pad using water hyacinth fibers and cotton, transforming an invasive aquatic weed into a sustainable absorbent material. Laboratory tests showed strong fluid absorption, safe pH levels, low microbial contamination, and rapid biodegradation.

17 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Cambridge’s LED breakthrough reinvents drug synthesis

Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than toxic chemicals – a discovery that could accelerate and improve how medicines are designed and made.

13 Mar 2026

UVA researcher receives $3.4 million grant to improve weight-management programs

A University of Virginia School of Medicine researcher has received $3.4 million from the National Institutes of Health to increase the availability of weight-management programs that offer beneficial personalized feedback.

12 Mar 2026

Real-world study shows modest weight regain after GLP-1 discontinuation

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings.

12 Mar 2026

Can eating almonds reduce inflammation in obesity?

Adding almonds to the diet of adults with obesity enhances inflammatory cytokine profiles and diet quality, highlighting a simple anti-inflammatory strategy.

12 Mar 2026

Wegovy linked to higher risk of eye stroke and vision loss

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

10 Mar 2026

Hormone asprosin linked to long-term weight changes after menopause

Researchers at the University of California, Irvine Joe C. Wen School of Population & Public Health have identified how the hormone asprosin influences long-term weight change among postmenopausal women in the United States.

10 Mar 2026

Most weight lost on GLP-1 drugs returns within a year after stopping

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies for effective long-term weight loss.

9 Mar 2026